Â Those risks and uncertainties include , but are not limited to , risks related to regulatory approvals and the success of Echo 's ongoing studies , including the efficacy of Echo 's Symphony tCGM System ( " Symphony " ) and Prelude SkinPrep System ( " Prelude " ) , the failure of future development and preliminary marketing efforts related to Symphony and Prelude , Echo 's ability to secure additional commercial partnering arrangements , risks and uncertainties relating to Echo 's ability to develop , market and sell diagnostic and transdermal drug delivery products based on its skin permeation platform technologies , including Symphony and Prelude , the availability of substantial additional equity or debt capital to support its research , development and product commercialization activities , and the success of its research , development , regulatory approval , marketing and distribution plans and strategies , including those plans and strategies related to Symphony and Prelude .